Vaccine (Peptide vaccine) · Immune activation, directed at neoantigens · developed by Agenus
AGEN2017 is a personalized autologous peptide vaccine composed of patient-specific neoantigen peptides complexed with heat shock protein 70 (HSP70). The vaccine elicits neoantigen-specific T-cell responses by presenting neoantigens to antigen-presenting cells, thereby targeting neoantigen-expressing cancer cells. It is studied in solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03673020 | Phase 1 | Solid Tumor, Adult | Completed | AGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumor, Adult
See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AGEN catalysts and pipeline →